12/12
07:05 pm
lly
Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win [Yahoo! Finance]
Low
Report
Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win [Yahoo! Finance]
12/12
02:03 pm
lly
Novo's Next Shot at Dominance: High-Dose Wegovy Takes Aim at Lilly's Zepbound [Yahoo! Finance]
Low
Report
Novo's Next Shot at Dominance: High-Dose Wegovy Takes Aim at Lilly's Zepbound [Yahoo! Finance]
12/12
12:18 pm
lly
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer [Yahoo! Finance]
Low
Report
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer [Yahoo! Finance]
12/12
11:45 am
lly
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
Low
Report
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
12/12
08:33 am
lly
Novo Nordisk Stumbles as Obesity Drug Race Heats Up [Yahoo! Finance]
Low
Report
Novo Nordisk Stumbles as Obesity Drug Race Heats Up [Yahoo! Finance]
12/12
07:22 am
lly
Think Eli Lilly Is Expensive? This Metric Says Otherwise. [Yahoo! Finance]
Low
Report
Think Eli Lilly Is Expensive? This Metric Says Otherwise. [Yahoo! Finance]
12/11
07:03 pm
lly
Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge? [Yahoo! Finance]
Low
Report
Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge? [Yahoo! Finance]
12/11
07:03 pm
lly
Missed Ozempic? Lilly's Next Drug Could Be Even Bigger [Yahoo! Finance]
Low
Report
Missed Ozempic? Lilly's Next Drug Could Be Even Bigger [Yahoo! Finance]
12/11
12:11 pm
lly
Eli Lilly (LLY) Stock Is Up, What You Need To Know [Yahoo! Finance]
Low
Report
Eli Lilly (LLY) Stock Is Up, What You Need To Know [Yahoo! Finance]
12/11
11:43 am
lly
Major weight loss, pain relief seen with Eli Lilly's next-gen drug in late-stage trial [FOX Business Network]
Low
Report
Major weight loss, pain relief seen with Eli Lilly's next-gen drug in late-stage trial [FOX Business Network]
12/11
11:22 am
lly
Eli Lilly: Retatrutide Justifies Hype With Best Weight Loss Data Yet - I'm Sold [Seeking Alpha]
Low
Report
Eli Lilly: Retatrutide Justifies Hype With Best Weight Loss Data Yet - I'm Sold [Seeking Alpha]
12/11
08:36 am
lly
Lilly Reports Positive Results in Next-Gen Obesity Drug Trial [Yahoo! Finance]
Low
Report
Lilly Reports Positive Results in Next-Gen Obesity Drug Trial [Yahoo! Finance]
12/11
08:25 am
lly
Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial [MSNBC.com]
Low
Report
Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial [MSNBC.com]
12/11
08:13 am
lly
Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly [MSNBC.com]
Low
Report
Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly [MSNBC.com]
12/11
07:22 am
lly
Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial [Yahoo! Finance]
Low
Report
Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial [Yahoo! Finance]
12/11
06:46 am
lly
Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial [CNBC]
Low
Report
Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial [CNBC]
12/11
06:45 am
lly
Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial
Low
Report
Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial
12/11
04:16 am
lly
Eli Lilly and Company (NYSE:LLY) had its "buy (b-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its "buy (b-)" rating reaffirmed by analysts at
Weiss Ratings.
12/11
03:42 am
lly
Novo Nordisk Is Trading as If Obesity Drug Craze Never Happened [Yahoo! Finance Canada]
Low
Report
Novo Nordisk Is Trading as If Obesity Drug Craze Never Happened [Yahoo! Finance Canada]
12/11
02:56 am
lly
Eli Lilly's Mounjaro Added to China's National Health Insurance for Diabetes [Yahoo! Finance]
Low
Report
Eli Lilly's Mounjaro Added to China's National Health Insurance for Diabetes [Yahoo! Finance]
12/10
03:23 pm
lly
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Wells Fargo & Company from $1,100.00 to $1,200.00. They now have an "overweight" rating on the stock.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Wells Fargo & Company from $1,100.00 to $1,200.00. They now have an "overweight" rating on the stock.
12/10
11:40 am
lly
Eli Lilly and Company (LLY) Announces Results From Phase 3 BRUIN CLL-314 Trial Evaluating Jaypirca Versus Imbruvica [Yahoo! Finance]
Low
Report
Eli Lilly and Company (LLY) Announces Results From Phase 3 BRUIN CLL-314 Trial Evaluating Jaypirca Versus Imbruvica [Yahoo! Finance]
12/10
07:21 am
lly
Eli Lilly and Company (NYSE:LLY) had its "hold" rating reaffirmed by analysts at HSBC Holdings plc.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its "hold" rating reaffirmed by analysts at HSBC Holdings plc.
12/9
03:30 pm
lly
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
Low
Report
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
12/9
08:28 am
lly
Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition
Low
Report
Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition